Oncology biotech Prelude guns for $100M IPO

Share

Fierce 15 winner Prelude Therapeutics is going for a $100M IPO as it looks to finish off early clinical work for its cancer drug candidate PRT543.

The biotech is targeting PRMT5, an enzyme related to treatment resistance and oncogenesis in both solid and hematological cancers. PRMT5 is overexpressed in several types of cancer, including solid and blood-based disease.

Read the full article at fiercebiotech.com…

Share

Comments are closed.